Thyroid nodule laboratory findings

Jump to navigation Jump to search

Thyroid nodule Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thyroid nodule from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thyroid nodule laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thyroid nodule laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thyroid nodule laboratory findings

CDC on Thyroid nodule laboratory findings

Thyroid nodule laboratory findings in the news

Blogs on Thyroid nodule laboratory findings

Directions to Hospitals Treating Thyroid nodule

Risk calculators and risk factors for Thyroid nodule laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laboratory Findings

Test Indication
Serum thyrotropin In all thyroid nodules
serum antithyroperoxidase level If suspected to Hashimoto's thyroiditis
Free T4 If suspected to hot, thyroid hormone producing nodule
T3 If suspected to thyrotoxicosis
Thyroglobulin May be elevated in most thyroid diseases and are an insensitive and nonspecific test for thyroid cancer Routine measurement is not recommended by ATA
basal serum calcitonin In patients with positive family history of medullary thyroid carcinoma

In any patients with family history of MEN

In any patients with concomitant hormonal abnormalities

greater than 100 pg=mL, medullary cancer is likely present 39

Routine measurement: there remain unresolved issues of sensitivity, specificity, assay performance and costeffectiveness
plasma metanephrine testing In patients suspected to MEN to evaluate pheochromocytoma
24-hour urinary collection

for catecholamines and metanephrines

  • Thyroid specific molecular markers may be helpful in patients with intermediate cytology on FNA to decide on disease management:
    • BRAF
    • RAS
    • RET = PTC
    • Pax8-PPARg
    • Galectin-3

References

Template:WH Template:WS